Mechanism of Action

Dapagliflozin amorphous acts similarly to dapagliflozin propanediol as an SGLT2 inhibitor. It interferes with glucose reabsorption in the proximal renal tubules by blocking SGLT2, leading to increased urinary glucose excretion and a reduction in blood glucose levels in patients with type 2 diabetes.

Indication

Indicated for the same use as Dapagliflozin, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.